We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dengue Rapid Diagnostic Kit Field Evaluated

By LabMedica International staff writers
Posted on 07 Jan 2013
Rapid diagnostic tests that detect proteins of and antibodies to the Dengue virus (DENV) are now available to be used in the field. More...


Dengue diagnosis is complex and until recently, only specialized laboratories were able to definitively confirm dengue infection, but the rapid tests are now available commercially making biological diagnosis possible in low resource settings.

Scientists at the Pasteur Institute (Phnom Penh, Cambodia) enrolled 157 patients hospitalized for a suspicion of dengue in a prospective study between June and October 2011. A panel of sera were chosen for positive and negative control and tested with reverse transcriptase polymerase chain reaction (RT-PCR), in-house immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay (MAC-ELISA), and a hemagglutination inhibition assay.

The rapid diagnostic used was the SD Bioline Dengue Duo kit (Standard Diagnostics (Kyonggi-do, Korea) and for the prospective study, only acute blood samples were tested. The SD Bioline Dengue Duo kit is composed of two tests designed to detect DENV NS1 antigen as a first test and anti-DENV IgM/IgG as a second test in serum, plasma, or whole blood. In the field hospital laboratories, the overall sensitivity was 85.7% and the specificity was 83.9% of the NS1/IgM/IgG combination tests, whereas in the national reference laboratory, the sensitivity was 94.4%, and the specificity was 90.0%.

The results of the study demonstrated that optimal performances require adequate training and quality assurance. The retrospective study showed that the sensitivity of the combined kit did not vary significantly between the serotypes and was not affected by the immune status or by the interval of time between onset of fever and sample collection. However, in the context of the prospective field study, it was shown that if the SD Bioline Dengue Duo kit is correctly used, a positive result highly suggests a dengue case, but a negative result does not rule out a dengue infection.

The authors concluded that when they assessed the impact of the test results on the clinical management decision, the physicians treated patients according to their clinical diagnosis and did not take negative results into consideration. The combination of NS1 test with antibodies detection improved the performance, though discordances on IgM and IgG results were observed between the hospitals and the national reference laboratories. The study was published online in December 2012 in the journal Public Library of Science Neglected tropical Diseases.

Related Links:

Cambodian Pasteur Institute
Standard Diagnostics




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.